Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial of ibrutinib (Imbruvica) in diffuse large B-cell lymphoma (DLBCL).

In a phase Ib/II trial combination of ibrutinib with lenalidomide (Revlimid) and rituximab (Rituxan) was tested in patients with the ABC subtype of DLBCL. Safety was determined first, and then in the phase II portion, the combination was tested at the maximum-tolerated dose. Ibrutinib with lenalidomide and rituximab was well tolerated up to a 25 mg dose of lenalidomide.

In the non-GCB subtype, there was a high overall response rate, and several patients did not have disease progression until after 1 year, says Beaupre.

Videos

Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell Lymphoma

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial exploring the efficacy of ibrutinib (Imbruvica) in patients with marginal zone lymphoma (MZL).

Because of the fact that MZL is usually trigged by chronic inflammation, researchers theorized that ibrutinib would be an effective treatment in this disease. A phase II trial led by Ariela Noy, MD, of Memorial Sloan Kettering Cancer Center, enrolled 63 patients with MZL treated with single-agent ibrutinib at 560 mg daily. The primary endpoint was overall response rate (ORR) with a secondary endpoint of duration of response.

Results showed that there was a nearly 50% ORR when analyzed by an independent review committee. Additionally, the duration of response was not reached, equating to a significant finding, he adds.

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial exploring the efficacy of ibrutinib in patients with marginal zone lymphoma.

Darrin M. Beaupre, MD

Articles

Dr. Beaupre on Ibrutinib in Diffuse Large B-Cell Lymphoma

Dr. Beaupre on Ibrutinib in Marginal Zone Lymphoma